Rob Sahr was quoted by IPWatchdog in an article titled “CAFC Issues Precedential Ruling on Proper Analysis for Patent Term Adjustment in Double Patenting Cases.” In this article, Rob discusses how In re Cellect has implications for pharmaceutical patents with Patent Term Extension (PTE) that have an earlier expiring family member due to Patent Term Adjustment (PTA).
“Perhaps most concerning, the Federal Circuit denied a requested remedy for invalidation of just the adjusted patent term, shutting off a potential safety valve to maintain the validity of PTE patent claims,” Rob said. Read more.
Related content: